Answers are grounded in this paper and cite their sources.
Immune checkpoint blockade (ICB) has advanced melanoma therapy, yet its efficacy remains limited by poor tumor immunogenicity and insufficient T-cell infiltration. To overcome these dual barriers, we develop BPC9@MnCO3, a biomimetic nanoplatform cloaked with PD-1-enriched melanoma membranes and loaded with chemokine CXCL9. The tumor-homing membrane coating directs nanoparticle accumulation in melanoma tissue. Additionally, PD-1 overexpression on the surface of B16-F10 cell membranes blocks the PD-1/PD-L1 signaling axis, thereby restoring T-cell immune function. Within the acidic tumor microenvironment, MnCO3 decomposes to release Mn2+ ions, which trigger immunogenic cell death (ICD) to enhance tumor antigen presentation. Meanwhile, the degradation of MnCO3 triggers membrane rupture, which increases local CXCL9 levels and leads to enhanced T-cell infiltration, thereby mediating a potent antitumor immune response. Notably, BPC9@MnCO3 significantly inhibits tumor growth and reduces the number of lung metastases in vivo. These effects are attributed to the ability of BPC9@MnCO3 to relieve immune checkpoint inhibition and induce ICD effects, effectively improving the immune microenvironment and significantly enhancing T-cell infiltration in tumor tissue. In summary, our work demonstrates a novel strategy to improve ICB efficacy by coordinately targeting immune activation and recruitment barriers.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: